TMC LIFE SCIENCES BHD — Interim / Quarterly Report 2026

May 19, 2026

TMC LIFE SCIENCES BERHAD

Company no. 200301021989 (624409-A)
(Incorporated in Malaysia)

UNAUDITED INTERIM FINANCIAL REPORT

FOR THE FINANCIAL QUARTER ENDED
31 MARCH 2026

Contact

Level 11, No.11, Jalan Teknologi,
Taman Sains Selangor 1, PJU 5,
Kota Damansara
47810 Petaling Jaya, Selangor D.E.
Tel: +603 6287 1111
Fax: +603 6287 1212
www.tmclife.com

---

TMC LIFE SCIENCES BERHAD
Company no. 200301021989 (624409-A)
(Incorporated in Malaysia)

UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME
FOR THE FINANCIAL PERIOD ENDED 31 MARCH 2026

	Individual Quarter		9 months ended
	Current Year Quarter
31/03/2026
RM'000	Preceding Year Quarter
31/03/2025
RM'000	Current Year To Date
31/03/2026
RM'000	Preceding Year Corresponding Period
31/03/2025
RM'000
Revenue	89,701	89,872	293,675	252,265
Other operating income	1,335	1,240	4,487	3,194
Inventories and consumables	(31,710)	(30,565)	(106,342)	(83,028)
Staff costs	(28,389)	(30,501)	(86,113)	(88,716)
Other operating expenses	(17,686)	(19,446)	(55,239)	(51,149)
Depreciation and amortisation	(9,424)	(9,058)	(28,172)	(24,906)
Interest income	728	801	2,158	3,461
Finance costs	(1,806)	(2,291)	(5,801)	(7,103)
Profit before taxation	2,749	52	18,653	4,018
Taxation	(991)	(858)	(5,921)	(2,835)
Profit / (Loss) for the financial period, representing total comprehensive income / (loss) (net of tax) for the financial period	1,758	(806)	12,732	1,183
Profit / (Loss) for the financial period, representing total comprehensive income / (loss) (net of tax) for the financial period attributable to:-
Owners of the parent	1,758	(806)	12,732	1,183
Profit / (Loss) per ordinary share attributable to the owners of the parent (sen)
Basic / Diluted	0.10	(0.05)	0.73	0.07

The unaudited condensed consolidated statement of comprehensive income should be read in conjunction with the accompanying explanatory notes attached to the unaudited interim financial statements.

---

TMC LIFE SCIENCES BERHAD
Company no. 200301021989 (624409-A)
(Incorporated in Malaysia)

UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY
FOR THE FINANCIAL PERIOD ENDED 31 MARCH 2026

	Attributable to owners of the parent			Total equity RM'000
	Share capital RM'000	Non-distributable	Distributable
		Share options reserve RM'000	Retained profits RM'000
Balance at 1 July 2025	625,986	-	227,057	853,043
Profit for the financial period, representing total comprehensive income (net of tax) for the financial period	-	-	12,732	12,732
Transaction with owners
Dividend paid	-	-	(3,245)	(3,245)
Balance at 31 March 2026	625,986	-	236,544	862,530
Balance at 1 July 2024	625,986	1,316	260,732	888,034
Profit for the financial year, representing total comprehensive income (net of tax) for the financial year	-	-	3,606	3,606
Transactions with owners
Share options granted under ESOS	-	19	-	19
Transfer within reserve for ESOS forfeited	-	(1,335)	1,335	-
Dividend paid	-	-	(38,616)	(38,616)
Total transactions with owners	-	(1,316)	(37,281)	(38,597)
Balance at 30 June 2025	625,986	-	227,057	853,043

The unaudited condensed consolidated statement of changes in equity should be read in conjunction with the audited financial statements for the financial year ended 30 June 2025 and the accompanying explanatory notes attached to the unaudited interim financial statements.

---

TMC LIFE SCIENCES BERHAD
Company no. 200301021989 (624409-A)
(Incorporated in Malaysia)

UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION

AS AT 31 MARCH 2026

| | As At
31/03/2026
Unaudited
RM'000 | As At
30/06/2025
Audited
RM'000 |
| --- | --- | --- |
| Non-current assets | | |
| Property, plant and equipment | 715,103 | 725,778 |
| Intangible assets | 196,836 | 201,192 |
| Investment property | 1,995 | 2,039 |
| Deferred tax assets | 701 | 700 |
| Total non-current assets | 914,635 | 929,709 |
| Current assets | | |
| Inventories | 18,638 | 15,908 |
| Trade and other receivables | 57,869 | 65,600 |
| Tax recoverable | 744 | 11,409 |
| Cash and bank balances | 118,116 | 109,564 |
| Total current assets | 195,367 | 202,481 |
| TOTAL ASSETS | 1,110,002 | 1,132,190 |
| Current liabilities | | |
| Contract liabilities | 553 | 519 |
| Trade and other payables | 58,540 | 69,286 |
| Borrowings | 45,109 | 38,047 |
| Lease liabilities | 1,827 | 1,901 |
| Income tax payable | 1,085 | 559 |
| Total current liabilities | 107,114 | 110,312 |
| NET CURRENT ASSETS | 88,253 | 92,169 |
| Non-current liabilities | | |
| Contract liabilities | 385 | 357 |
| Borrowings | 107,757 | 141,426 |
| Lease liabilities | 1,460 | 1,598 |
| Provision | 663 | 739 |
| Deferred tax liabilities | 30,093 | 24,715 |
| Total non-current liabilities | 140,358 | 168,835 |
| TOTAL LIABILITIES | 247,472 | 279,147 |
| NET ASSETS | 862,530 | 853,043 |
| Represented by: | | |
| Equity attributable to owners of the parent | | |
| Share capital | 625,986 | 625,986 |
| Retained profits | 236,544 | 227,057 |
| TOTAL EQUITY | 862,530 | 853,043 |
| Net assets per share (RM) | 0.50 | 0.49 |

The unaudited condensed consolidated statement of financial position should be read in conjunction with the audited financial statements for the financial year ended 30 June 2025 and the accompanying explanatory notes attached to the unaudited interim financial statements.

4

---

TMC LIFE SCIENCES BERHAD
Company no. 200301021989 (624409-A)
(Incorporated in Malaysia)

UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS FOR THE FINANCIAL PERIOD ENDED 31 MARCH 2026

| | Current Year
To Date
31/03/2026
RM'000 | Preceding Year
Corresponding
Period
31/03/2025
RM'000 |
| --- | --- | --- |
| Cash flows from operating activities | | |
| Profit before tax | 18,653 | 4,018 |
| Adjustments for :- | | |
| Non-cash items | 28,948 | 25,683 |
| Interest expense | 5,801 | 7,103 |
| Interest income | (2,158) | (3,461) |
| Operating profit before changes in working capital | 51,244 | 33,343 |
| Changes in working capital | | |
| Net change in current assets | 4,217 | (18,245) |
| Net change in trade and other payables and contract liabilities | (10,761) | 5,273 |
| Cash generated from operations | 44,700 | 20,371 |
| Interest paid | (5,629) | (6,951) |
| Net income tax refunded / (paid) | 10,648 | (1,586) |
| Net cash flows generated from operating activities | 49,719 | 11,834 |
| Cash flows from investing activities | | |
| Acquisition of property, plant and equipment | (10,756) | (30,487) |
| Acquisition of intangible assets | (712) | (449) |
| Proceeds from disposal of property, plant and equipment | 9 | 3 |
| Withdrawal of deposits placed with:- | | |
| - financial institutions with original maturity of more than three (3) months | 28,589 | 32,562 |
| - deposits pledged | 90 | 210 |
| Interest received | 2,158 | 3,461 |
| Net cash flows generated from investing activities | 19,378 | 5,300 |
| Cash flows used in financing activities | | |
| Dividend paid | (3,245) | (38,616) |
| Payment of lease liabilities | (1,850) | (1,822) |
| Repayment of term loans | (26,331) | (15,075) |
| Repayment of hire purchase | (441) | (662) |
| Net cash flows used in financing activities | (31,867) | (56,175) |
| Net increase/(decrease) in cash & cash equivalents | 37,230 | (39,041) |
| Cash & cash equivalents at beginning of the financial period | 60,822 | 107,511 |
| Cash & cash equivalents at end of the financial period | 98,052 | 68,470 |
| Cash & cash equivalents at end of the financial period | | |
| Cash at banks and on hand | 58,696 | 49,642 |
| Deposits with licenced banks | 59,420 | 67,117 |
| | 118,116 | 116,759 |
| Less: Deposits with licensed banks (for more than 3 months) | (16,048) | (44,299) |
| Deposit pledged to a licenced bank | (1,556) | (1,530) |
| Cash restricted in use | (2,460) | (2,460) |
| | 98,052 | 68,470 |

The unaudited condensed consolidated statement of cash flows should be read in conjunction with the accompanying explanatory notes attached to the unaudited interim financial statements.

---

TMC LIFE SCIENCES BERHAD
Company no. 200301021989 (624409-A)
(Incorporated in Malaysia)

NOTES TO THE UNAUDITED INTERIM FINANCIAL REPORT

FOR THE FINANCIAL PERIOD ENDED 31 MARCH 2026

A EXPLANATORY NOTES PURSUANT TO MALAYSIAN FINANCIAL REPORTING STANDARDS ("MFRS")

A1 BASIS OF PREPARATION

The interim financial report is unaudited and has been prepared in compliance with Malaysian Financial Reporting Standards ("MFRS") 134 - Interim Financial Reporting and paragraph 9.22 of the Main Market Listing Requirements of Bursa Malaysia Securities Berhad.

The interim financial report should be read in conjunction with the audited financial statements of TMC Life Sciences Berhad and its subsidiaries ("the Group") for the financial year ended 30 June 2025. The explanatory notes attached to the unaudited interim financial statements provide an explanation of events and transactions that are significant for understanding the changes in the financial position of the Group since the financial year ended 30 June 2025, and changes in financial performance since the preceding year corresponding period.

The accounting policies and methods of computations used in the preparation of the unaudited interim financial statements are consistent with those adopted in the audited financial statements for the financial year ended 30 June 2025, except for the adoption of the new, revised and amendments to MFRS and IC Interpretations effective as of 1 January 2025 as issued by the Malaysian Accounting Standards Board, which does not have any significant impact on the unaudited interim financial statements of the Group.

A2 SEASONALITY OR CYCLICALITY OF OPERATIONS

The Group's business is typically impacted during festive and holiday periods when a decrease in patient load is anticipated.

A3 UNUSUAL ITEMS AFFECTING ASSETS, LIABILITIES, EQUITY, NET INCOME OR CASH FLOWS

There were no material items or events that arose, which affected assets, liabilities, equity, net income or cash flows that are unusual by reasons of their nature, size or incidence.

A4 CHANGE IN ACCOUNTING ESTIMATES

There were no material changes in the nature and amount of estimates reported that have a material effect in the current financial quarter under review.

A5 ISSUANCE AND REPAYMENT OF DEBT AND EQUITY SECURITIES

There were no issuance, cancellation, repurchases, resale and repayment of debt and equity securities in the current financial quarter under review.

---

7

A6 DIVIDEND PAID

During the financial period ended 31 March 2026, the Company paid a final single tier dividend of 0.1863 sen per ordinary share on 1,741,882,393 ordinary shares, amounting to RM3,245,111 in respect of the financial year ended 30 June 2025.

A7 SEGMENTAL INFORMATION

The Group operates mainly in Malaysia and is involved in the healthcare sector which includes providing specialist healthcare services in its multi disciplinary tertiary hospital and fertility centres.

A8 MATERIAL EVENT SUBSEQUENT TO THE END OF THE INTERIM REPORTING PERIOD

There was no material event subsequent to 31 March 2026 and up to the date of this report that would likely affect substantially the results of the operations of the Group.

A9 CHANGES IN THE COMPOSITION OF THE GROUP

There were no changes in the composition of the Group during the current quarter under review.

A10 CONTINGENT LIABILITIES OR CONTINGENT ASSETS

| Financial guarantees | 31/03/2026
RM'000 | 30/06/2025
RM'000 |
| --- | --- | --- |
| Unsecured | | |
| Corporate guarantees given to licensed bank for banking facility granted to wholly-owned subsidiaries | 152,866 | 179,473 |
| Letter of guarantee given to suppliers | 3,948 | 9,225 |
| | 156,814 | 188,698 |

A11 CAPITAL COMMITMENTS

The amount of commitments for capital expenditure is as follows:

| | 31/03/2026
RM'000 | 30/06/2025
RM'000 |
| --- | --- | --- |
| Approved and contracted for | 40,685 | 29,581 |

A12 SIGNIFICANT RELATED PARTY TRANSACTIONS

There were no significant related party transactions during the quarter under review.

---

TMC LIFE SCIENCES BERHAD

Company no. 200301021989 (624409-A)

(Incorporated in Malaysia)

NOTES TO THE UNAUDITED INTERIM FINANCIAL REPORT

FOR THE FINANCIAL PERIOD ENDED 31 MARCH 2026

B ADDITIONAL INFORMATION REQUIRED BY BURSA MALAYSIA SECURITIES BERHAD ("BURSA SECURITIES")

B1 REVIEW OF THE PERFORMANCE OF THE GROUP

Analysis of performance

Review of results for the financial quarter (3 months ended 31 March 2026 versus 3 months ended 31 March 2025)

	3 months ended
	31/03/2026	31/03/2025
	RM'000	RM'000
Revenue	89,701	89,872
Profit before taxation	2,749	52

For the quarter ended 31 March 2026, the Group recorded revenue of RM89.7 million and profit before taxation of RM2.7 million, an improvement in profit before taxation compared to the previous corresponding quarter. This performance was due to continued cost optimisation initiatives.

Review of results for the financial period (9 months ended 31 March 2026 versus 9 months ended 31 March 2025)

	9 months ended
	31/03/2026	31/03/2025
	RM'000	RM'000
Revenue	293,675	252,265
Profit before taxation	18,653	4,018

For the financial period ended 31 March 2026, the Group reported a $16\%$ increase in revenue to RM293.7 million and an improvement in profit before taxation of RM18.7 million, compared to the same period ended 31 March 2025. This performance was driven by the rebound in hospital revenue and continued cost optimisation initiatives.

Material factors affecting the earnings and / or revenue of the Group

The material factors that affect the earnings and / or revenue of the Group are the successful recruitment of healthcare professionals in our facilities, additional bed capacity and additional services offered by the Group, higher case intensity handled, and continuous marketing effort to boost local and international branding.

B2 MATERIAL CHANGE IN PROFIT BEFORE TAX AS COMPARED WITH IMMEDIATE PRECEDING QUARTER

(3 months ended 31 March 2026 versus 3 months ended 31 December 2025)

	3 months ended
	31/03/2026	31/12/2025
	RM'000	RM'000
Revenue	89,701	103,497
Profit before taxation	2,749	9,336

Compared to the immediate preceding quarter ended 31 December 2025, revenue and profit before taxation declined by $13\%$ and $71\%$ , respectively. The decrease in profit before taxation was attributable to a lower patient load during the festive and prolonged public holiday periods.

---

9

B3 PROSPECTS FOR THE FINANCIAL YEAR ENDING 30 JUNE 2026

The private healthcare landscape continues to be shaped by evolving payor dynamics, with insurers and corporate customers placing increased emphasis on affordability, efficiency and value-based outcomes. In response, the Group is proactively executing its value-based care strategy. This approach focuses on delivering high-quality clinical outcomes in a financially sustainable manner, ensuring we remain a preferred partner for insurers while maintaining our commitment to excellence in patient care.

The impact of global geopolitical situation may cause supply chain disruptions and inflationary pressures. However, the Group has strengthened its operational resilience through cost optimisation and the diversification of procurement sourcing in preparation of any potentiality.

The Group's growth trajectory remains robust, underpinned by the increased capacity at Thomson Hospital Kota Damanasara and the strategic expansion of key specialties. The Group is also actively diversifying its revenue base by strengthening its presence in the corporate segment, broadening its international patient mix, and scaling its fertility business to capture regional demand, thereby sustaining long-term shareholder value.

B4 VARIANCE ON PROFIT FORECAST/PROFIT GUARANTEE

There is no profit forecast or profit guarantee for the financial period ended 31 March 2026

B5 TAXATION

	Individual quarter		9 months ended
	31/03/2026	31/03/2025	31/03/2026	31/03/2025
	RM'000	RM'000	RM'000	RM'000
In respect of current quarter / financial period
Current tax expense	56	236	542	1,530
Deferred tax expense	935	622	5,379	1,305
	991	858	5,921	2,835

Tax provision during the current quarter refers to recognition of tax expense for profit making subsidiaries.

B6 STATUS OF CORPORATE PROPOSAL

There are no corporate proposals announced but not completed as at 13 May 2026, being the latest practicable date which shall not be earlier than 7 days from the date of this quarterly report.

B7 BORROWINGS

The Group's borrowings are as follows:

	Long Term	Short Term	Total
	RM'000	RM'000	RM'000
As at 31 March 2026
Secured - Denominated in Ringgit Malaysia	107,757	45,109	152,866
As at 30 June 2025
Secured - Denominated in Ringgit Malaysia	141,426	38,047	179,473

Included in the Group's borrowings is industrial hire purchase of NIL as at the reporting date (30 June 2025: RM442,000).

B8 MATERIAL LITIGATION

There was no material litigation as at the date of this report.

---

B9 DIVIDENDS

The Board does not recommend any dividend for the current quarter under review (previous year corresponding period ended 31 March 2025: NIL)

B10 EARNINGS PER SHARE (EPS)

	Individual quarter		9 months ended
	31/03/2026	31/03/2025	31/03/2026	31/03/2025
Basic / Diluted EPS
Net profit / (loss) attributable to owners of the parent (RM'000)	1,758	(806)	12,732	1,183
Weighted average number of ordinary shares in issue ('000)	1,741,882	1,741,882	1,741,882	1,741,882
EPS (sen)
- Basic / Diluted	0.10	(0.05)	0.73	0.07

B11 AUDITORS' REPORT ON PRECEDING ANNUAL FINANCIAL STATEMENTS

The audit report of the preceding annual financial statements was unqualified.

B12 NOTE TO STATEMENT OF COMPREHENSIVE INCOME

	Individual quarter		9 months ended
	31/03/2026 RM'000	31/03/2025 RM'000	31/03/2026 RM'000	31/03/2025 RM'000
Interest income	728	801	2,158	3,461
Interest expense	(1,804)	(2,288)	(5,795)	(7,092)
Unwinding of discount on provision for restoration	(2)	(3)	(6)	(11)
Depreciation of property, plant and equipment, investment property and right-of-use assets	(7,695)	(7,355)	(22,997)	(20,742)
Amortisation of intangible assets	(1,729)	(1,703)	(5,175)	(4,164)
Impairment loss on receivables	(299)	(210)	(719)	(630)
Fair value charges on share options granted under ESOS	-	(5)	-	(15)
Property, plant and equipment written off	(14)	(1)	(30)	(13)
Gain on disposal of property, plant and equipment	6	2	9	2
Gain on provision of restoration	19	-	19	-
Gain on derecognition of lease liability	-	1	8	1
Inventories written off	(14)	(14)	(63)	(122)

B13 DERIVATIVE FINANCIAL INSTRUMENTS

The Group did not enter into any derivative financial instruments which were outstanding as at 31 March 2026 and 30 June 2025.

B14 AUTHORISED FOR ISSUE

The unaudited condensed consolidated interim financial statements were authorised for issue by the Board of Directors in accordance with a resolution of the Directors on 20 May 2026.